 |
|
|
| |
Sofosbuvir/Velpatasvir in Combination With Ribavirin for 24 Weeks Is Effective Retreatment for Patients Who Failed Prior NS5A-Containing DAA Regimens: Results of the Retreatment Study
|
| |
| |
Reported by Jules Levin
APASL 2017 Feb 15-19 Shanghai, China
Edward J. Gane1, Mitchell L. Shiffman2, Kyle Etzkorn3, Giuseppe Morelli4, Catherine Stedman5, Mitchell N. Davis6, Federico Hinestrosa7, Jina Lee8, Joseph Llewellyn8, Hadas Dvory-Sobol8, K.C. Huang8, Anu Osinusi8, John McNally8, Diana M. Brainard8, John G. McHutchison8, Alex Thompson9, Mark Sulkowski10
1Auckland Clinical Studies, Auckland, New Zealand; 2Liver Institute of Virginia, Richmond, Virginia, USA; 3Borland Groover Clinic, Jacksonville, Florida, USA; 4University of Florida, Gainesville, Florida, USA; 5Christchurch Clinical Studies Trust, Christchurch, New Zealand; 6South Florida Center of Gastroenterology, Wellington, Florida, USA; 7Orlando Immunology Center, Orlando, Florida, USA; 8Gilead Sciences, Inc., Foster City, California, USA; 9St Vincent's Hospital, Melbourne, Australia; 10Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
|
| |
|
|
|
|
|
